A Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

Phase 1

Recruiting

• Conditions: Advanced Solid Tumors
• Interventions: Drug: DB-1311

• Registration Number: NCT05914116
• Lead Sponsor: DualityBio Inc.

Brief Summary

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.

Detailed Description

This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a study. Phase 1 adopts an accelerated titration at first dose level followed with classic "3+3" design to identify the MTD and/or RP2D. Phase 2a is a dose expansion phase to confirm the safety, tolerability and explore efficacy in selected malignant solid tumors treated with DB-1311/BNT324 as monotherapy.

Study Timeline

• Study First Submitted: 2023-06-13
• Study First Submitted QC: 2023-06-13
• Study First Posted: 2023-06-22
• Study Start: 2023-08-17
• Status Verified: 2025-05
• Last Update Submitted: 2025-05-13
• Last Update Posted: 2025-05-16
• Primary Completion: 2026-09
• Study Completion: 2026-09

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 610

Inclusion Criteria

1. Male or female adults (defined as ≥ 18 years of age or acceptable age according to local regulations at the time of voluntarily signing of informed consent).

2. Histologically or cytologically confirmed unresectable advanced/metastatic solid tumor that has relapsed or progressed on or after standard systemic treatments, or is intolerable with standard treatment; or for which no standard treatment is available.

3. At least one measurable lesion as assessed by the investigator according to response evaluation criteria in solid tumors (RECIST) version 1.1 criteria (measurable disease as defined by RANO 2.0 criteria for GBM subjects). Castrate-resistant prostate cancer (CRPC) subjects with bone only disease may be eligible on a case-by- case basis after discussion with the Medical Monitor.

4. Has a life expectancy of ≥ 3 months.

5. Has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1.

6. Has LVEF ≥ 50% by either echocardiography (ECHO) or multiple-gated acquisition (MUGA) within 28 days before enrollment.

7. Has adequate organ function within 7 days prior to Day 1 of Cycle 1

8. Has adequate treatment washout period prior to Day 1 of Cycle 1

9. Is willing to provide pre-existing resected tumor samples or undergo fresh tumor biopsy for the measurement of B7-H3 level and other biomarkers if no contraindication.

   Note: there is no minimum B7-H3 expression level mandatory for entry into the study.

10. Is capable of comprehending study procedures and risks outlined in the informed consent and able to provide written consent and agree to comply with the requirements of the study and the schedule of assessments.

11. Male and female subjects of reproductive/childbearing potential must agree to use adequate contraceptive methods (e.g., double barrier or intrauterine contraceptive) during the study and for at least 4 months and 7 months after the last dose of study drug, respectively.

12. Male subjects must not freeze or donate sperm starting at screening and throughout the study period, and at least 4 months after the final study drug administration.

13. Female subjects must not donate, or retrieve for their own use, ova from the time of screening and throughout the study treatment period, and for at least 7 months after the final study drug administration.

14. SCLC subjects (Phase 2a Cohort 1 ONLY):

    • Pathologically documented locally advanced, or metastatic SCLC not amenable to curative surgery or radiation.
    • Prior therapy with at least one platinum-based line as systemic therapy for extensive stage disease with at least two cycles of therapy (except in the case of early objective PD).
    • Prior treatment regimens with irinotecan, topotecan or any other TOP I inhibitor including investigational TOP I inhibitors are not allowed.

15. NSCLC subjects (Phase 2a Cohort 2 ONLY):

    • Pathologically documented locally advanced, or metastatic NSCLC and is not amenable to curative surgery or radiation.
    • Has received prior treatment with platinum-based chemotherapy regimen and/or anti-PD-1/PD-L1 antibody-based regimen in the advanced/unresectable, or metastatic setting unless unable or unwilling. Subjects with NSCLC known to harbor a genomic alteration(s) other than EGFR mutation(s) (e.g., ALK rearrangement, ROS1 rearrangement, KRAS G12C mutation, BRAF V600E mutation, NTRK1/2/3 Gene fusion, MET Exon 14 skipping, RET rearrangement etc.) for which treatment is available must have also received prior treatment with at least 1 genotype-directed therapy.

16. ESCC subjects (Phase 2a Cohort 3 ONLY):

    • Pathologically documented locally advanced, or metastatic ESCC and is not amenable to curative surgery or radiation.
    • Having received at least one prior therapy for unresectable disease. Patients with recurrence within 6 months of completion of neoadjuvant or adjuvant therapy will be considered as having received one prior therapy for unresectable disease.

17. CRPC subjects (Phase 2a Cohort 4 ONLY):

    • Pathologically documented metastatic adenocarcinoma of the prostate cancer.
    • Progressive metastatic CRPC as defined: 1) castrate levels of serum testosterone < 50 ng/dL AND 2) progressive disease as defined by PCWG3 criteria.
    • Having received prior docetaxel (before or after an AR-targeted therapy). Docetaxel rechallenge was allowed.
    • Having received prior novel hormone therapy.

18. Melanoma subjects (Phase 2a Cohort 5 ONLY)

    • Histologically or cytologically confirmed diagnosis of unresectable Stage III or metastatic melanoma not amenable to local therapy, must have had either:

    • Previously treated with a PD-1 or PD-L1 inhibitor.
    • If subjects with BRAF gene mutant melanoma, must have had a prior treatment regimen that included vemurafenib, dabrafenib, or another BRAF gene and/or mitogen-activated protein kinase (MEK) protein inhibitor.

19. HCC subjects (Phase 2a Cohort 6 ONLY)

    • Histological/cytological confirmed diagnosis of HCC or clinically confirmed diagnosis of HCC as per American Association for the Study of Liver Diseases (AASLD) criteria (fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC are not eligible), and:
    • Has received 1 or 2 prior systemic therapy regimens for recurrent or metastatic disease;
    • Has experienced disease progression during or after treatment with an anti-PD-1/L1 agent administered either as monotherapy or in combination.

    Note: Subjects basically should receive prior standard therapy.

    • However, if the investigator judges the therapy is not appropriate for the subject, the prior standard therapy is not necessarily mandated for the eligibility.
    • Has a Child-Pugh class A liver score within 7 days of first dose of study drug.

20. Cervical cancer subjects (Phase 2a Cohort 7 ONLY)

    • Has recurrent or metastatic cervical cancer with squamous cell, adenocarcinoma, or adenosquamous histology, and:

    • Has experienced disease progression during or after treatment with a standard of care systemic chemotherapy doublet, or platinum-based therapy (if eligible), defined as either:

      d. paclitaxel + cisplatin + bevacizumab + anti-PD-(L)1 agent, or e. paclitaxel + carboplatin + bevacizumab + anti-PD-(L)1 agent, or f. paclitaxel + topotecan + bevacizumab + anti-PD-(L)1 agent Note: In cases where bevacizumab and/or anti-PD-(L)1 agent is not a standard of care therapy or the subject was ineligible for such treatment according to local standards, prior treatment with bevacizumab and/or anti-PD-(L)1 agent is not required.

    • Has received 1 or 2 prior systemic therapy regimens for recurrent or metastatic cervical cancer. Chemotherapy administered in the adjuvant or neoadjuvant setting, or in combination with radiation therapy, should not be counted as a systemic therapy regimen. Single agent therapy with an anti-PD(L)1 agent for recurrent or metastatic cervical cancer should be counted.

21. Subjects with other solid tumors (Phase 2a Cohort 8 ONLY)

    • Histologically or cytologically confirmed solid tumors.
    • Progressed or relapsed after at least one prior standard therapeutic regimen (Patients who have not received all approved or standard treatments for their cancer must be informed that these alternatives to receiving DB-1311/BNT324 are available prior to consenting to participate in this trial).

22. HNSCC subjects (Phase 2a Cohort 9 and Cohort 13)

    • Histologically or cytologically confirmed refractory/metastatic (R/M) HNSCC (not including NPC) that is considered incurable by local therapies.
    • Progressed on or after prior standard therapeutic regimen.

23. Subjects with rare tumors (Phase 2a Cohort 10 ONLY) Histologically or cytologically confirmed rare tumor types. Progressed or relapsed after at least one prior standard therapeutic regimen (Patients who have not received all approved or standard treatments for their cancer must be informed that these alternatives to receiving DB-1311/BNT324 are available prior to consenting to participate in this trial).

24. Post lutetium-177 CRPC subjects (Phase 2a Cohort 11 ONLY):

    Pathologically documented metastatic adenocarcinoma of the prostate cancer. Progressive metastatic CRPC as defined: 1) castrate levels of serum testosterone < 50 ng/dL AND 2) progressive disease as defined by PCWG3 criteria.

25. Taxane-naive CRPC subjects (Phase 2a Cohort 12 ONLY) • Pathologically documented metastatic adenocarcinoma of the prostate cancer. Progressive metastatic CRPC as defined: 1) castrate levels of serum testosterone < 50 ng/dL AND 2) progressive disease as defined by PCWG3 criteria.

Exclusion Criteria

Unless otherwise specified, the exclusion criteria are common to both Phase 1 and Phase 2a. Subjects who meet any of the following criteria will be excluded from the study:

1. Prior treatment with B7-H3 targeted therapy.
2. Prior treatment with antibody drug conjugate with topoisomerase inhibitor (e.g., trastuzumab deruxtecan).
3. Has a medical history of symptomatic congestive heart failure (CHF) (New York Heart Association [NYHA] classes II-IV) or serious cardiac arrhythmia requiring treatment.
4. Has a medical history of myocardial infarction or unstable angina within 6 months before enrollment.
5. Has an average of Fredericia's formula-QT corrected interval (QTcF) prolongation to > 470 millisecond (ms) in males and females based on a 12-lead electrocardiogram (ECG) in triplicate.
6. Unable or unwilling to discontinue concomitant drugs that are known to prolong the QT interval.
7. Has a medical history of interstitial lung diseases (e.g., non-infectious interstitial pneumonia, pneumonitis, pulmonary fibrosis, and severe radiation pneumonitis) or current interstitial lung diseases or who are suspected to have these diseases by imaging at screening.
8. Has a history of underlying pulmonary disorder including, but not limited to, pulmonary emboli within 3 months of the start of study treatment, severe asthma, severe COPD, restrictive lung disease, and other clinically significant pulmonary compromise or requirement for supplemental oxygen.
9. Clinically significant gastrointestinal disorder including, but not limited to, history of gastrointestinal fistulation that need long-term intravenous nutrition; gastrointestinal dysfunction that need long-term enteral nutrition through the tube feeding; gastrointestinal obstruction/perforation that not recovered within 6 months prior to the enrollment.
10. Untreated or incompletely treated esophageal and/or gastric varices with bleeding or high risk of bleeding; A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study treatment (Only applicable to HCC patients).
11. Metastatic disease that involves major airways or blood vessels (e.g., patients with vascular invasion of the major portal vein and inferior vena cava).
12. Clinically uncontrolled pleural effusion, ascites or pericardial effusion requiring drainage, peritoneal shunt or cell-free concentrated ascites reinfusion therapy within 2 weeks prior to the enrollment.
13. Any autoimmune, connective tissue or inflammatory disorders (e.g., rheumatoid arthritis, Sjögren's, sarcoidosis) where there is documented, or a suspicion of pulmonary involvement at the time of screening.
14. Has an uncontrolled infection requiring intravenous injection of antibiotics, antivirals, or antifungals.
15. Know human immunodeficiency virus (HIV) infection.
16. Subjects have active viral (any etiology) hepatitis are excluded. However, subjects with serologic evidence of chronic hepatitis B virus (HBV) infection (defined by a positive hepatitis B surface antigen [HBsAg] test or a positive hepatitis B core antibody test) who have a viral load below the limit quantification (e.g., HBV DNA titer < 1000 cps/mL or 200 IU/mL) and are willing to and maintain antiviral treatment are eligible. However, subjects with a history of hepatitis C virus (HCV) infection who have completed curative antiviral treatment and have a viral load below the limit of quantification are eligible for study entry.
17. Is a lactating mother (women who are willing to temporarily interrupt breastfeeding will also be excluded), or pregnant as confirmed by pregnancy tests performed within 7 days prior to enrollment.
18. Has spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms. Subjects with clinically inactive brain metastases may be included in the study. Subjects with treated brain metastases that are no longer symptomatic and who require no treatment with corticosteroids or anticonvulsants may be included in the study if they have recovered from the acute toxic effect of radiotherapy. A minimum of 2 weeks must have elapsed between the end of whole brain radiotherapy and study randomization.
19. Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to NCI-CTCAE version 5.0, grade ≤ 1 or baseline. Subjects with chronic Grade 2 toxicities (e.g., Grade 2 neuropathy) may be eligible based on the discussion and agreement between Investigator and Sponsor.
20. Has multiple primary malignancies within 3 years before enrollment, except adequately resected non-melanoma skin cancer (e.g., resected basal or squamous cell skin cancer), curatively treated in-situ disease (e.g., carcinoma in situ of the cervix or breast), other solid tumors curatively treated (e.g., superficial bladder cancer), or contralateral breast cancer.
21. Has substance abuse or any other medical conditions that would increase the safety risk to the subject or interfere with participation or evaluation of the clinical study in the opinion of the investigator.
22. Has known hypersensitivity to either the drug substances or inactive ingredients in the drug product.
23. Patients with other reasons that, in the opinion of the Investigator, make them unsuitable to participate in this study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
DB-1311/BNT324 Dose Level 1	DB-1311	Enrolled Subjects will receive a single-dose of DB-1311/BNT324 at Dose Level 1 on Day 1 of each cycle Q3W
DB-1311/BNT324 Dose Level 2	DB-1311	Enrolled Subjects will receive a single-dose of DB-1311/BNT324 at Dose Level 2 on Day 1 of each cycle Q3W
DB-1311/BNT324 Dose Level 3	DB-1311	Enrolled Subjects will receive a single-dose of DB-1311/BNT324 at Dose Level 3 on Day 1 of each cycle Q3W
DB-1311/BNT324 Dose Level 4	DB-1311	Enrolled Subjects will receive a single-dose of DB-1311/BNT324 at Dose Level 4 on Day 1 of each cycle Q3W
DB-1311/BNT324 Dose Level 5	DB-1311	Enrolled Subjects will receive a single-dose of DB-1311/BNT324 at Dose Level 5 on Day 1 of each cycle Q3W
DB-1311/BNT324 Dose Expansion 1	DB-1311	Subjects with advanced/unresectable, or metastatic SCLC who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311/BNT324.
DB-1311/BNT324 Dose Expansion 2	DB-1311	Subjects with advanced/unresectable, or metastatic NSCLC who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311/BNT324.
DB-1311/BNT324 Dose Expansion 3	DB-1311	Subjects with advanced/unresectable, or metastatic esophageal squamous cell carcinoma (ESCC) who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311/BNT324.
DB-1311/BNT324 Dose Expansion 4	DB-1311	Subjects with advanced/unresectable, or metastatic castration-resistant prostate cancer (CRPC) who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311/BNT324.
DB-1311/BNT324 Dose Expansion 5	DB-1311	Subjects with advanced/unresectable, or metastatic melanoma who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311/BNT324.
DB-1311/BNT324 Dose Expansion 6	DB-1311	Subjects with advanced/unresectable, or metastatic HCC who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311/BNT324.
DB-1311/BNT324 Dose Expansion 7	DB-1311	Subjects with advanced/unresectable, or metastatic cervical cancer who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311/BNT324.
DB-1311/BNT324 Dose Expansion 8	DB-1311	Subjects with other advanced or metastatic solid tumors who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311/BNT324.
DB-1311/BNT324 Dose Expansion 9	DB-1311	Subjects with advanced/unresectable, or metastatic HNSCC (not including NPC) who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311/BNT324.
DB-1311/BNT324 Dose Expansion 10	DB-1311	Subjects with advanced or metastatic rare tumor types who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311/BNT324.
DB-1311/BNT324 Dose Expansion 11	DB-1311	Subjects with advanced/unresectable, or metastatic CRPC who have progressed on or after standard systemic treatments including no more than 2 lines of systemic chemotherapy, novel hormone therapy and lutetium-177 radioligand therapy, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311/BNT324.
DB-1311/BNT324 Dose Expansion 12	DB-1311	Taxane-naive subjects with advanced/unresectable, or metastatic CRPC who have progressed on or after novel hormone therapy, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311/BNT324.
DB-1311/BNT324 Dose Expansion 13	DB-1311	Subjects with advanced/unresectable, or metastatic HNSCC (not including NPC) who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311/BNT324.

Primary Outcome Measures

Name	Time	Method
Phase 1: Percentage of Participants with Dose-Limiting Toxicities (DLTs) as assessed by CTCAE v5.0. Percentage of participants in Part 1 with DLTs	up to 21 days after Cycle 1 Day 1	Percentage of participants in Part 1 with DLTs
Phase 1: Percentage of Participants with Treatment Emergent Adverse Events (TEAEs) as assessed by CTCAE v5.0.	Up to follow-up period, approximately 1 year post-treatment	Percentage of participants with TEAEs in Part 1 graded according to NCI CTCAE v5.0
Phase 1: Percentage of Participants with Serious Adverse Events (SAEs) as assessed by CTCAE v5.0.	Up to follow-up period, approximately 1 year post-treatment	Percentage of Participants with SAEs in Part 1 graded according to NCI CTCAE v5.0
Maximum Tolerated Dose (MTD) of DB-1311/BNT324	Up to the completion of Part 1 (assessed up to 12 months)	MTD on the data collected during Part 1
Phase 1: Recommended Phase 2 Dose (RP2D) of DB-1311/BNT324	Up to the completion of Part 1 (assessed up to 12 months)	RP2D of DB-1311/BNT324 based on the data collected during Part 1
Phase 2a: Percentage of Participants with Treatment Emergent adverse events (TEAEs) as assessed by CTCAE v5.0.	Up to follow-up period, approximately 1 year post-treatment	Percentage of participants with TEAEs in Part 2 graded according to NCI CTCAE v5.0
Phase 2a: Percentage of participants with Serious Adverse Events (SAEs) as assessed by CTCAE v5.0.	Up to follow-up period, approximately 1 year post-treatment	Percentage of participants with SAEs in Part 2 graded according to NCI CTCAE v5.0
Phase 2a: Objective Response Rate (ORR) as determined by investigator	Up to follow-up period, approximately 1 year post-treatment	Phase 2a: Objective Response Rate (ORR) as determined by investigator per RECIST 1.1 in non-CRPC/non-GBM participants, ORR as determined by investigator per RECIST v1.1 for soft tissue and Prostate Cancer Working Group 3 (PCWG3) criteria for bone metastases in CRPC participants, ORR as determined by neuro-oncology 2.0 (RANO 2.0) criteria for GBM participants. The percentage of participants who had a best response rating of CR and PR, for Part 2 only which was maintained ≥4 weeks

Secondary Outcome Measures

Name	Time	Method
Phase 1 & Phase 2a: Overall Survival (OS)	From date of first dose until the date of death or lost to follow up, approximately 1 year post-treatment	OS is defined as the time from date of first dose to the date of death.
Phase 1 & Phase 2a: Pharmacokinetic-AUC	within 8 cycles (each cycle is 21 days)	Area under the concentration-time curve from time 0 to infinity of DB-1311/BNT324 ADC, total anti-B7-H3 antibody, and unconjugated P1021
Phase 1 & Phase 2a: Pharmacokinetic-Tmax	within 8 cycles (each cycle is 21 days)	Time to Cmax of DB-1311/BNT324 ADC, total anti-B7-H3 antibody, and unconjugated P1021
Phase 1 & Phase 2a: Pharmacokinetic-Cthrough	within 8 cycles (each cycle is 21 days)	Trough concentration
Phase 1 & 2a: ADA incidence	Up to follow-up period, approximately 1 year post-treatment	Percentage of participants having treatment-emergent ADA
Phase 1: Objective response rate (ORR)	Up to follow-up period, approximately 1 year post-treatment	ORR will be determined from tumor assessments by investigator per response evaluation criteria in solid tumors version 1.1 (RECIST v1.1)
Phase 1 & Phase 2a: duration of response (DoR)	Up to follow-up period, approximately 1 year post-treatment	DoR will be determined from tumor assessments by investigator per response evaluation criteria in solid tumors version 1.1 (RECIST v1.1)
Phase 1 & Phase 2a: disease-control rate (DCR)	Up to follow-up period, approximately 1 year post-treatment	DCR will be determined from tumor assessments by investigator per response evaluation criteria in solid tumors version 1.1 (RECIST v1.1)
Phase 1 & Phase 2a: Time to Response (TTR)	Up to follow-up period, approximately 1 year post-treatment	TTR will be determined from tumor assessments by investigator per response evaluation TTR criteria in solid tumors version 1.1 (RECIST v1.1)
Phase 1 & Phase 2a: Progression Free Survival (PFS)	Up to follow-up period, approximately 1 year post-treatment	PFS will be determined from tumor assessments by investigator per response evaluation PFS criteria in solid tumors version 1.1 (RECIST v1.1)
Prostate-specific antigen (PSA)	From date of first dose until the date of first PSA progression, approximately 1 year post-treatment	Time to PSA progression, PSA50 response rate and PSA90 response rate, duration of PSA response in CRPC subjects.
Phase 1 & Phase 2a: Pharmacokinetic-Cmax	within 8 cycles (each cycle is 21 days)	Maximum observed plasma concentration (Cmax) of DB-1311/BNT324 ADC, total anti-B7-H3 antibody, and unconjugated P1021
Phase 1 & 2a: Anti-drug antibody (ADA) prevalence	Up to follow-up period, approximately 1 year post-treatment	Percentage of participants who are ADA positive at any point

Trial Locations

Locations (98)

Research Site 317; 🇨🇳 Xinxiang, Henan, China

Research Site 111; 🇺🇸 Tucson, Arizona, United States

Research Site 125; 🇺🇸 Los Angeles, California, United States

Research Site 133; 🇺🇸 Los Angeles, California, United States

Research Site 103; 🇺🇸 Los Angeles, California, United States

Research Site 128; 🇺🇸 Santa Monica, California, United States

Research Site 118; 🇺🇸 Celebration, Florida, United States

Research Site 127; 🇺🇸 Margate, Florida, United States

Research Site 101; 🇺🇸 Plantation, Florida, United States

Research Site 109; 🇺🇸 Tamarac, Florida, United States

Research Site 114; 🇺🇸 Atlanta, Georgia, United States

Research Site 115; 🇺🇸 Louisville, Kentucky, United States

Research Site 129; 🇺🇸 Detroit, Michigan, United States

Research Site 121; 🇺🇸 Saint Paul, Minnesota, United States

Research Site 110; 🇺🇸 Las Vegas, Nevada, United States

Research Site 107; 🇺🇸 New York, New York, United States

Research Site 113; 🇺🇸 Cincinnati, Ohio, United States

Research Site 131; 🇺🇸 Dayton, Ohio, United States

Research Site 123; 🇺🇸 Charleston, South Carolina, United States

Research Site 108; 🇺🇸 Greenville, South Carolina, United States

Research Site 120; 🇺🇸 Dallas, Texas, United States

Research Site 102; 🇺🇸 Fairfax, Virginia, United States

Research Site 112; 🇺🇸 Fairfax, Virginia, United States

Research Site 105; 🇺🇸 Spokane, Washington, United States

Research Site 208; 🇦🇺 Blacktown, New South Wales, Australia

Research Site 215; 🇦🇺 Camperdown, New South Wales, Australia

Research Site 212; 🇦🇺 Concord, New South Wales, Australia

Research Site 217; 🇦🇺 New Lambton Heights, New South Wales, Australia

Research Site 201; 🇦🇺 Sydney, New South Wales, Australia

Research Site 205; 🇦🇺 Sydney, New South Wales, Australia

Research Site 206; 🇦🇺 Sydney, New South Wales, Australia

Research Site 216; 🇦🇺 Waratah, New South Wales, Australia

Research Site 209; 🇦🇺 Birtinya, Queensland, Australia

Research Site 203; 🇦🇺 Brisbane, Queensland, Australia

Research Site 210; 🇦🇺 Gold Coast, Queensland, Australia

Research Site 202; 🇦🇺 Nedlands, Western Australia, Australia

Research Site 207; 🇦🇺 Nedlands, Western Australia, Australia

Research Site 319; 🇨🇳 Hefei, Anhui, China

Research Site 365; 🇨🇳 Beijing, Beijing, China

Research Site 310; 🇨🇳 Beijing, Beijing, China

Research Site 337; 🇨🇳 Beijing, Beijing, China

Research Site 327; 🇨🇳 Chongqing, Chongqing, China

Research Site 345; 🇨🇳 Chongqing, Chongqing, China

Research Site 353; 🇨🇳 Chongqing, Chongqing, China

Research Site 356; 🇨🇳 Chongqing, Chongqing, China

Research Site 313; 🇨🇳 Fuzhou, Fujian, China

Research Site 314; 🇨🇳 Guangzhou, Guangdong, China

Research Site 322; 🇨🇳 Guangzhou, Guangdong, China

Research Site 346; 🇨🇳 Guangzhou, Guangdong, China

Research Site 348; 🇨🇳 Guangzhou, Guangdong, China

Research Site 350; 🇨🇳 Guangzhou, Guangdong, China

Research Site 360; 🇨🇳 Nanning, Guangxi, China

Research Site 334; 🇨🇳 Baoding, Hebei, China

Research Site 315; 🇨🇳 Harbin, Heilongjiang, China

Research Site 316; 🇨🇳 Luoyang, Henan, China

Research Site 306; 🇨🇳 Zhengzhou, Henan, China

Research Site 304; 🇨🇳 Zhengzhou, Henan, China

Research Site 321; 🇨🇳 Wuhan, Hubei, China

Research Site 311; 🇨🇳 Wuhan, Hubei, China

Research Site 309; 🇨🇳 Changsha, Hunan, China

Research Site 323; 🇨🇳 Changsha, Hunan, China

Research Site 344; 🇨🇳 Nanjing, Jiangsu, China

Research Site 305; 🇨🇳 Nanjing, Jiangsu, China

Research Site 307; 🇨🇳 Ganzhou, Jiangxi, China

Research Site 349; 🇨🇳 Nanchang, Jiangxi, China

Research Site 361; 🇨🇳 Nanchang, Jiangxi, China

Research Site 328; 🇨🇳 Changchun, Jilin, China

Research Site 301; 🇨🇳 Changchun, Jilin, China

Research Site 320; 🇨🇳 Shenyang, Liaoning, China

Research Site 352; 🇨🇳 Shenyang, Liaoning, China

Research Site 363; 🇨🇳 Nanjing, Nanjing, China

Research Site 340; 🇨🇳 Jinan, Shandong, China

Research Site 308; 🇨🇳 Jinan, Shandong, China

Research Site 333; 🇨🇳 Linyi, Shandong, China

Research Site 302; 🇨🇳 Linyi, Shandong, China

Research Site 335; 🇨🇳 Shanghai, Shanghai, China

Research Site 326; 🇨🇳 Shanghai, Shanghai, China

Research Site 355; 🇨🇳 Shanghai, Shanghai, China

Research Site 332; 🇨🇳 Xi'an, Shanxi, China

Research Site 312; 🇨🇳 Chengdu, Sichuan, China

Research Site 325; 🇨🇳 Chengdu, Sichuan, China

Research Site 330; 🇨🇳 Chengdu, Sichuan, China

Research Site 347; 🇨🇳 Tianjin, Tianjin, China

Research Site 318; 🇨🇳 Tianjin, Tianjin, China

Research Site 324; 🇨🇳 Hangzhou, Zhejiang, China

Research Site 329; 🇨🇳 Hangzhou, Zhejiang, China

Research Site 331; 🇨🇳 Hangzhou, Zhejiang, China

Research Site 359; 🇨🇳 Hangzhou, Zhejiang, China

Research Site 303; 🇨🇳 Taizhou, Zhejiang, China

Research Site 408; 🇨🇳 Kaohsiung, Taiwan

Research Site 405; 🇨🇳 Kaohsiung, Taiwan

Research Site 406; 🇨🇳 New Taipei City, Taiwan

Research Site 401; 🇨🇳 Taipei, Taiwan

Research Site 402; 🇨🇳 Taipei, Taiwan

Research Site 409; 🇨🇳 Taipei, Taiwan

Research Site 403; 🇨🇳 Taipei, Taiwan

Research Site 407; 🇨🇳 Taipei, Taiwan

Research Site 404; 🇨🇳 Taoyuan, Taiwan